The Ion's Aerospace Innovation Accelerator for Minority Business Enterprises has named four companies to its first cohort. Photo courtesy of The Ion

A new accelerator program that is focused on aerospace innovation and supporting entrepreneurs who are Black, Indigenous, and people of color has announced its first cohort.

The Ion's Aerospace Innovation Accelerator for Minority Business Enterprises, or AIA for MBEs, has named the four companies that well be a part of its inaugural cohort. The 12-week program will guide the entrepreneurs through the development of their innovations, the growth of their businesses, and the development of relationships with mentors, corporate partners, and stakeholder networks.

"Aerospace contains a myriad of dimensions and by demystifying the industry in the form of the AIA for MBEs, we are able to build a more inclusive innovation ecosystem," says Christine Galib, senior director of programs at The Ion, in a news release. "It's our goal to not only support participants to be successful, but to open the playing field for other minority business enterprises hoping to enter the space."

The program's existence was possible through a partnership with NASA's Johnson Space Center, DivInc, and The Ion — as well as a $1.4 million grant from the U.S. Department of Commerce's Minority Business Development Agency.

Here are the four companies to take part in the cohort, according to the release:

  • Axialnics Systems Inc., led by Vincent Mbuvi, is an aerospace technology platform developing a Disc-wing Rotor Aircraft Concept, which takes-off as a helicopter, carries as much payload as an airplane and flies just as fast beyond the range of typical helicopters. The innovation solves runway inefficiencies and enhances military efficiency.
  • Boozed Beverages LLC, led by Damyanna Cooke and Jim Luu, specializes in intelligent vending in the liquor industry. The company provides a contactless, AI-driven cocktail making and dispensing vending machine, for locations such as weddings and events, sporting venues, festivals, restaurants, and nightclubs and lounges.
  • NANCo Aero, led by Shern Peters, provides urban air vehicles and drones to commercial, small business, government, and nonprofit organizations. It is working to develop the first Hybrid Personal Air Vehicle capable of transporting a family over the city of Houston.
  • Stratos Perception LLC, led by Rube Williams, develops artificial intelligence solutions for space systems to benefit human productivity, safety, and enterprise. It is also developing an intelligent transducer, a tool that can monitor and control multiphase flow, for use in space such as lunar water extraction and waste processing.

The hub and its associated accelerator will be housed at The Ion when it opens up later this year — along with the organizations other accelerators — but the program is being launched virtually on Wednesday, April 21, at noon.

"The Aerospace Innovation Hub came from the idea that the aerospace industry is well-known in Houston but for many people, particularly underrepresented communities, there have been barriers in entering the aerospace industry," says Jan E. Odegard, executive director of The Ion, in the release. "By offering mentorship, introduction to capital and training opportunities, with significant backing from Microsoft, The Ion is working to remove the barriers."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”